Streetbeat News

Stock Prices

AZN

AstraZeneca is reportedly considering spinning off its China business and listing a separate unit in Hong Kong amid geopolitical tensions. China accounted for 13% of the company's overall sales in 2022. The spin-off could protect AstraZeneca from tensions while retaining business control.

Portfolio Pulse from Vandana Singh

June 20, 2023 | 12:23 pm

BDRX

Biodexa Pharmaceuticals (NASDAQ:BDRX) has appealed the Staff Determination from the Nasdaq Listing Qualifications Department to delist its securities due to closing bid prices below $0.10 for ten consecutive trading days and failure to meet the Minimum Bid Price Rule. The company has until July 31, 2023, to regain compliance.

Portfolio Pulse from Happy Mohamed

June 20, 2023 | 12:21 pm

AAPL

Apple Inc.'s M1 MacBook Air from 2020 is now available at a discounted price of $799, down from $999 on Amazon. The M1 chip offers efficiency, battery life, and performance-per-watt, making it a solid contender in the thin and light laptop category.

Portfolio Pulse from Sudhanshu Singh

June 20, 2023 | 12:20 pm

ACLX

GILD

TSVT

The FDA has placed a clinical hold on Arcellx Inc's (NASDAQ:ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA, a drug for relapsed or refractory multiple myeloma, following a recent patient death. Arcellx is working with the FDA to amend the protocol. Kite, a Gilead Sciences Inc (NASDAQ:GILD) company, announced a collaboration with Arcellx in December 2022 to co-develop and co-commercialize CART-ddBCMA.

Portfolio Pulse from Vandana Singh

June 20, 2023 | 12:19 pm

CANO

Cano Health shares rose 13.6% in pre-market trading after announcing a change in executive leadership to advance stockholder value creation. Other pre-market gainers include Evelo Biosciences, EBET, Biofrontera, Tivic Health Systems, voxeljet AG, SunCar Technology Group, Oncorus, Ideanomics, and Revelation Biosciences. Losers include Surgalign Holdings, Faraday Future Intelligent Electric, Dragonfly Energy Holdings, Arcellx, Beamr Imaging, Cyclacel Pharmaceuticals, Infinity Pharmaceuticals, IronNet, Missfresh, and WeWork.

Portfolio Pulse from Lisa Levin

June 20, 2023 | 12:10 pm

ENTG

Entegris (NASDAQ:ENTG) has received 4 bullish, 2 somewhat bullish, and 1 indifferent analyst ratings in the last quarter. The average price target is $106.86, slightly above the current price of $106.51. The average has increased by 1.77% from the previous target of $105.00.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 12:07 pm

GTES

Over the past 3 months, 6 analysts have published their opinion on Gates Industrial Corp (NYSE:GTES) stock, with an average 12-month price target of $16.08. The current average has increased by 3.21% from the previous average price target of $15.58.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 12:06 pm

NVCT

Nuvectis Pharma (NVCT) is set to join the Russell 2000 and Russell 3000 indexes, which could lead to increased visibility and trading volume for the stock.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 12:05 pm

CB

In the last quarter, Chubb (NYSE:CB) received 1 bullish, 7 somewhat bullish, and 2 indifferent ratings from analysts. The average 12-month price target for Chubb is $238.6, a 3.66% decrease from the previous average of $247.67.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 12:05 pm

OB

Over the past 3 months, 5 analysts have published their opinions on Outbrain (NASDAQ:OB) stock, with an average 12-month price target of $6.0, representing a 16.32% decrease from the previous average price target of $7.17.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 12:04 pm